Crossref
The cost-effectiveness and budget impact of zoledronic acid as adjuvant therapy in postmenopausal women with early breast cancer
Journal of Chinese Pharmaceutical Sciences · 30.03.2026 · 35 (3) · 292
DOI: 10.5246/jcps.2026.03.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chinese Pharmaceutical Sciences, online erschienen am 10.03.2026.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). The cost-effectiveness and budget impact of zoledronic acid as adjuvant therapy in postmenopausal women with early breast cancer. Journal of Chinese Pharmaceutical Sciences, 35(3), 292. https://doi.org/10.5246/jcps.2026.03.020
Vancouver
The cost-effectiveness and budget impact of zoledronic acid as adjuvant therapy in postmenopausal women with early breast cancer. Journal of Chinese Pharmaceutical Sciences. 2026;35(3):292. doi:10.5246/jcps.2026.03.020
BibTeX
@article{euvimed2026,
title = {The cost-effectiveness and budget impact of zoledronic acid as adjuvant therapy in postmenopausal women with early breast cancer},
journal = {Journal of Chinese Pharmaceutical Sciences},
year = {2026},
volume = {35},
number = {3},
pages = {292},
doi = {10.5246/jcps.2026.03.020}
}
EUVIMED